![](/img/cover-not-exists.png)
PCN5 BUDGET IMPACT ANALYSIS OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. ORAL IBANDRONATE OR IV GENERIC PAMIDRONATE IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES: A UK NHS PERSPECTIVE
M Botteman, M Aapro, J Stephens, JW Hay, J BrandmanVolume:
8
Year:
2005
Language:
english
DOI:
10.1016/s1098-3015(10)62911-7
File:
PDF, 65 KB
english, 2005